Skip to content

Clinical trials

Completed Glucose Intolerance trials in the United States

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Glucose Intolerance Status: Completed Country / region: United States Clear all

236 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20001
20012
20023
20035
20045
20058
200610
200711
20088
200913
20108
201118
20129
20138
201414
20155
201614
201712
201816
201912
20207
202118
202214
20232
20247
20253

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed236

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
University of California, Los Angeles7
Yale University6
Clinical Nutrition Research Center, Illinois Institute of Technology5
Mayo Clinic5
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)5
The University of Texas Health Science Center at San Antonio5
Duke University4
NYU Langone Health4
National Heart, Lung, and Blood Institute (NHLBI)4
Stanford University4

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Glucose Intolerance236
Obesity62
Diabetes Mellitus45
Diabetes Mellitus, Type 244
Insulin Resistance44
Metabolic Syndrome30
Prediabetic State27
Overweight19
Hypertension14
Hyperglycemia9

Trials

Showing 1 to 25 of 236. Each trial links to its page on Pharma Observatory.

136 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.